IP Verse

Liraglutide In Cardiovascular Conditions

PatentPatent Analysis

EP3423082

NOVO NORDISK
Application Number
EP17710160A
Filing Date
Mar 3, 2017
Status
Granted And Under Opposition
Jul 2, 2021
Grant Date
Aug 4, 2021
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP3300721B2
EP2729202B2
EP3897582B1

Biblio Summary

The patent EP3423082B1 was granted to Novo Nordisk on Aug 4, 2021 following the initial filing on Mar 3, 2017 under the application number EP17710160A . The current legal status of the patent is Granted And Under Opposition.

AI Generated Summary New

Patent Family

Patent Oppositions filed by Competitors

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

DR SCHONMay 4, 2022ADMISSIBLE
STADA ARZNEIMITTELMay 4, 2022ADMISSIBLE
ADALVOMay 3, 2022ADMISSIBLE
SANDOZMay 3, 2022ADMISSIBLE
TEVA PHARMACEUTICALSApr 28, 2022ADMISSIBLE

Dossier Documents of the Patent

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents